Search results
Showing 801 to 850 of 1515 results for patients and public
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]
Awaiting development Reference number: GID-TA11744 Expected publication date: TBC
Awaiting development Reference number: GID-TA11743 Expected publication date: TBC
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]
Awaiting development Reference number: GID-TA11667 Expected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Awaiting development Reference number: GID-TA11755 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC
In development Reference number: GID-TA11229 Expected publication date: TBC
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
In development Reference number: GID-TA11803 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]
Awaiting development Reference number: GID-TA11325 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
We are listening to your views on this Interventional procedures guidance. Comments close 19 February 2026.
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke
In development Reference number: GID-IPG10439 Expected publication date: TBC
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Extracorporeal shockwave therapy for Achilles tendinopathy (HTG426)
Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
Awaiting development Reference number: GID-TA11784 Expected publication date: 21 July 2027
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC
In development Reference number: GID-TA11425 Expected publication date: TBC
Awaiting development Reference number: GID-TA11494 Expected publication date: TBC
Awaiting development Reference number: GID-TA11326 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Awaiting development Reference number: GID-TA11840 Expected publication date: TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
Pharyngeal electrical stimulation for neurogenic dysphagia (HTG709)
Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.
View recommendations for HTG709Show all sections
In development Reference number: GID-TA11356 Expected publication date: TBC
Evidence-based recommendations on tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. This involves taking limbal stem cells from a living or deceased donor, growing them in the laboratory and transplanting them onto the patient’s affected eye(s).
View recommendations for HTG139Show all sections
Sections for HTG139
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development Reference number: GID-TA11284 Expected publication date: TBC
Awaiting development Reference number: GID-TA11863 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC